Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Vitamin D and Mortality in Heart Failure (EVITA)

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Heart and Diabetes Center North-Rhine Westfalia
ClinicalTrials.gov Identifier:
NCT01326650
First received: March 29, 2011
Last updated: July 15, 2014
Last verified: July 2014

March 29, 2011
July 15, 2014
November 2010
June 2016   (final data collection date for primary outcome measure)
Number of participants who died during the intervention [ Time Frame: three years ] [ Designated as safety issue: No ]
all-cause mortality (any cause of death) will be assessed
Same as current
Complete list of historical versions of study NCT01326650 on ClinicalTrials.gov Archive Site
  • Number of event-free survivors [ Time Frame: three years ] [ Designated as safety issue: No ]
    event defined as: cardiac transplantation, high urgent listing for cardiac transplantation, resuscitation, hospitalization, ventricular assist device implantation
  • Changes in biochemical risk markers [ Time Frame: three years ] [ Designated as safety issue: No ]
    inflammation markers, kidney parameters, lipid parameters, haemostasis parameters
  • Number of participants with elevated safety parameters [ Time Frame: every 6 months ] [ Designated as safety issue: Yes ]

    Serum 25-Hydroxyvitamin D should not exceed 150 ng/ml.

    Serum calcium should not exceed 2.75 mmol/l.

  • Number of event-free survivors [ Time Frame: three years ] [ Designated as safety issue: No ]
    event defined as: death from any course, cardiac transplantation, high urgent listing for cardiac transplantation, rescucitation, hospitalisation, ventricular assist device implantation
  • Changes in biochemical risk markers [ Time Frame: three years ] [ Designated as safety issue: No ]
    inflammation markers, kidney parameters, lipid parameters, haemostasis parameters
  • Number of participants with elevated safety parameters [ Time Frame: every 6 months ] [ Designated as safety issue: Yes ]

    Serum 25-Hydroxyvitamin D should not exceed 150 ng/ml.

    Serum calcium should not exceed 2.75 mmol/l.

Not Provided
Not Provided
 
Vitamin D and Mortality in Heart Failure
Effect of Vitamin D on All-cause Mortality in Heart Failure Patients

Despite significant therapeutic improvements, congestive heart failure (CHF) patients still have a poor prognosis. Currently, 5-year survival rates are only 35-50%. There is an accumulating body of evidence from prospective cohort studies that low circulating 25-hydroxyvitamin D is an independent predictor of all-cause and cardiovascular mortality, respectively. Vitamin D deficiency is prevalent among CHF patients. We hypothesize that vitamin D may improve survival in CHF patients. We therefore aimed to investigate whether vitamin D supplementation reduces mortality and increases event-free survival in end-stage CHF patients.

Not Provided
Interventional
Phase 4
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Congestive Heart Failure
  • Drug: Vitamin D
    daily oral vitamin D supplement of 100 micrograms for three years
  • Drug: placebo
    daily oral placebo supplement for three years
  • Experimental: Vitamin D
    daily vitamin D supplement
    Intervention: Drug: Vitamin D
  • Placebo Comparator: placebo
    Intervention: Drug: placebo

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
400
June 2016
June 2016   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • > 18 years of age and < 80 years of age
  • New York Heart Association Functional Class > = II

Exclusion Criteria:

  • pregnancy and lactation
  • sarcoidosis
  • daily vitamin D intake > 20 micrograms
  • serum 25-hydroxyvitamin D > 30 ng/ml
  • hypercalcemia
Both
18 Years to 79 Years
No
Contact information is only displayed when the study is recruiting subjects
Germany
 
NCT01326650
004
Yes
Heart and Diabetes Center North-Rhine Westfalia
Heart and Diabetes Center North-Rhine Westfalia
Not Provided
Study Chair: Armin Zittermann, PhD Heart Center North Rhine-Westphalia
Principal Investigator: Jochen Börgermann, MD Heart Center North Rhine-Westphalia
Heart and Diabetes Center North-Rhine Westfalia
July 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP